Blood Sugar Take Care and Glucose Metabolism
2013年3月11日 更新者:NewChapter, Inc.
Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study
This prospective international clinical trial is a two-arm, double-blind, randomized, placebo-controlled, parallel-group, multicenter study.
112 prediabetic subjects will be randomized to Blood Sugar Take Care or placebo.
Randomization will be stratified by gender.
The intervention period is 12 weeks.
The primary outcome is fasting glucose levels.
研究概览
研究类型
介入性
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
California
-
San Francisco、California、美国、94109
- SPRIM
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
SUBJECT INCLUSION CRITERIA: STEP 1
- Age ≥ 18 years
Subject meets American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals:
- If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia
If age <45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the following risk factors:
- Have a first-degree relative with diabetes
- Habitually physically inactive
- Race is African-American, Hispanic American, Native American, Asian American, or Pacific Islander
- Have delivered a baby weighing >9 lb or have been diagnosed with gestational diabetes mellitus
- Hypertensive (≥140/90)
- Known HDL cholesterol level 35 mg/dl
- Known triglyceride level ≥250 mg/dl
- On previous testing, had impaired glucose tolerance or impaired fasting glucose
- History of vascular disease
- Stable body weight (<5% change) in the last 3 months
- Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
- Able to understand the nature and purpose of the study including potential risks and side effects
- Willing to consent to study participation and to comply with study requirements
SUBJECT EXCLUSION CRITERIA
- Known diabetes (type I or II)
- Recent use (within 2 weeks of screening) of any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose or lipid metabolism
- Recent use (within 4 weeks of screening) of any prescription or OTC medication that significantly affects glucose or lipid metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and bile acid sequestrants
- Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use acceptable)
- Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
- Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
- Eating disorder
- Polycystic ovary syndrome
- Known allergies to any substance in the study product
- Pregnant or breastfeeding women
- History of alcohol, drug, or medication abuse
- Participation in another study with any investigational product within 3 months of screening
- Recent (<3 months) gastrointestinal surgery or any planned surgery during the treatment period
SUBJECT INCLUSION CRITERIA: STEP 2
1. Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading
SUBJECT INCLUSION CRITERIA: STEP 3
- Impaired fasting glucose, based on the American Diabetes Association definition of fasting serum glucose between 100 and 125 mg/dl
- Impaired glucose tolerance, based on the American Diabetes Association definition of serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Multiherb product
Herbal product
|
One 1200 mg soft gel capsule administered 3X/day for duration of study
其他名称:
|
|
安慰剂比较:Placebo
Maltodextrin control
|
One 1200 mg soft-gel capsule administered 3X/day for duration of study
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
空腹血糖
大体时间:12周
|
12周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
不良事件
大体时间:12周
|
12周
|
|
|
血压
大体时间:12周
|
12周
|
|
|
胰岛素敏感性指数
大体时间:12周
|
12周
|
|
|
空腹胰岛素
大体时间:12周
|
12周
|
|
|
Homeostasis Model Assessment of Insulin Resistance
大体时间:12 weeks
|
12 weeks
|
|
|
Quantitative insulin sensitivity check index
大体时间:12 weeks
|
12 weeks
|
|
|
Insulin secretion/insulin resistance index
大体时间:12 weeks
|
12 weeks
|
|
|
糖化血红蛋白 (HbA1c)
大体时间:12周
|
12周
|
|
|
High-sensitivity C-reactive protein
大体时间:12 weeks
|
12 weeks
|
|
|
High-molecular weight adiponectin
大体时间:12 weeks
|
12 weeks
|
|
|
Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)
大体时间:12 weeks
|
12 weeks
|
|
|
Body composition
大体时间:12 weeks
|
height/weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio
|
12 weeks
|
|
WHO Quality of Life Questionnaire
大体时间:12 weeks
|
12 weeks
|
|
|
Comprehensive metabolic panel
大体时间:12 weeks
|
12 weeks
|
|
|
全血细胞计数
大体时间:12周
|
12周
|
|
|
Gastrointestinal Symptom Rating Scale
大体时间:12 weeks
|
12 weeks
|
|
|
Pulse
大体时间:12 weeks
|
12 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Larry Miller, PhD、Sprim Advanced Life Sciences
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2012年6月1日
初级完成 (预期的)
2013年10月1日
研究完成 (预期的)
2013年11月1日
研究注册日期
首次提交
2012年3月7日
首先提交符合 QC 标准的
2012年3月13日
首次发布 (估计)
2012年3月14日
研究记录更新
最后更新发布 (估计)
2013年3月12日
上次提交的符合 QC 标准的更新
2013年3月11日
最后验证
2013年3月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.